Investor Presentation Full Year 2021
106
Investor presentation
Full year 2021
Rest of World at a glance.
Rest of World
Diabetes trend
Million
Diabetes market by value and
Novo Nordisk market share
DKK
billion
30%
Novo Nordisk reported sales
Full year 2021
Sales
(mDKK)
Growth²
200
Total GLP-13
4,050
85%
80%
Long-acting insulin4
2,265
17%
30%
150
60
Premix insulin5
2,409
3%
31%1
GLP-1
60%
Fast-acting insulin
2,161
6%
40
100
202
155
119
50
40
1%1
Insulin
Human insulin
2,609
19%
40%
Total insulin
9,444
11%
Other Diabetes care?
499
(23%)
20
5%1
OAD
20
Diabetes care
13,993
24%
20%
Obesity care
1,247
32%
(SaxendaⓇ)
0
2019
0
0%
Diabetes & Obesity
15,240
24%
2030
2045
Nov
2016
Nov
2021
care
Population with diabetes
Diabetes growth rate
Biopharm³
4,572
5%
GLP-1 MS
-Insulin MS
OAD MS
Total
19,812
19%
Diabetes trend estimates based on the following International Diabetes Foundation
defined regions: South & Central America, Southeast Asia
International Diabetes Federation: Diabetes Atlas 1th Edition 2000 and Diabetes Atlas
9th Edition 2019
1 CAGR calculated for last 5-year period
Competitor insulin value market shares, as of Nov 2021: Novo Nordisk 57%, Sanofi
24% and Eli Lilly 14%; Competitor GLP-1 value market shares, as of Nov 2021: Novo
Nordisk 57%, Eli Lilly 41% and AstraZeneca 2%
OAD: Oral anti-diabetic; MS: Market Share; Source: IQVIA MAT, Nov 2021 value
figures
2 At constant exchange rates; 3 Comprises Victoza®, OzempicⓇ and RybelsusⓇ;
4 Comprises TresibaⓇ, XultophyⓇ and LevemirⓇ; 5 Comprises NovoMixⓇ and
RyzodegⓇ: 6 Comprises NovoRapidⓇ and FiaspⓇ:7 Comprises Novo NormⓇ and
needles; 8 Comprises primarily Esperoct®, Refixia ®, NovoSevenⓇ, Novo Eight®
and NorditropinⓇView entire presentation